59
Views
6
CrossRef citations to date
0
Altmetric
Case Report

Anti-TNF therapy in the management of ocular attacks in an elderly patient with long-standing Behçet’s disease

, &
Pages 301-304 | Published online: 27 Sep 2016

References

  • EverekliogluCCurrent concepts in the etiology and treatment of Behçet diseaseSurv Ophthalmol200550429735015967189
  • KitaichiNMiyazakiAIwataDOhnoSStanfordMRChamsHOcular features of Behçet’s disease: an international collaborative studyBr J Ophthalmol200791121579158218024808
  • DaWZhuJWangLLuYAdalimumab for Crohn’s disease after infliximab treatment failure: a systematic reviewEur J Gastroenterol Hepatol201325888589123817447
  • SmolenJSEmeryPFleischmannRAdjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trialLancet2014383991432133224168956
  • LeonardiCPappKStroberBThe long-term safety of adalimumab treatment in moderate to severe psoriasis: a comprehensive analysis of all adalimumab exposure in all clinical trialsAm J Clin Dermatol201112532133721834597
  • Behçet’s Disease Research Committee of JapanBehçet’s disease: guide to diagnosis of Behçet’s diseaseJpn J Ophthalmol197418291294
  • LahayeCTatarZDubostJJSoubrierMOverview of biologic treatments in the elderlyJoint Bone Spine201582315416025553833
  • LobatónTFerranteMRutgeertsPBalletVVan AsscheGVermeireSEfficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel diseaseAliment Pharmacol Ther201542444145126104047
  • BaertFNomanMVermeireSInfluence of immunogenicity on the long-term efficacy of infliximab in Crohn’s diseaseN Engl J Med2003348760160812584368
  • LiuJSylwestrzakGRuggieriAPDeVriesAIntravenous versus subcutaneous anti-TNF-alpha agents for Crohn’s disease: a comparison of effectiveness and safetyJ Manag Care Spec Pharm201521755956626108380
  • KruhJNYangPSuelvesAMFosterCSInfliximab for the treatment of refractory noninfectious uveitis: a study of 88 patients with long-term follow-upOphthalmology2014121135836424011995
  • SuhlerEBLowderCYGoldsteinDAAdalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trialBr J Ophthalmol201397448148623376607
  • Díaz-LlopisMSalomDGarcia-de-VicuñaCTreatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patientsOphthalmology201211981575158122525047
  • PerraDAlbaMACallejasJLAdalimumab for the treatment of Behçet’s disease: experience in 19 patientsRheumatology (Oxford)201251101825183122723596
  • TakaseKOhnoSIdeguchiHUchioETakenoMIshigatsuboYSuccessful switching to adalimumab in an infliximab-allergic patient with severe Behçet disease-related uveitisRheumatol Int201131224324519816689
  • MushtaqBSaeedTSitunayakeRDMurrayPIAdalimumab for sight-threatening uveitis in Behçet’s diseaseEye (Lond)200721682482516601736